Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | EDNRA | P25101 | 6/20 | 0.39 |
| ▸ | EDNRB | P24530 | 5/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16383003 | 0.82 | HPGDS (0.43) | MAPK1PRMT6HPGDSEDNRAEDNRB | |
| SCHEMBL12648428 | 0.80 | NOTUM (0.50) | MAPK1PRMT6HPGDSLTA4HHCRTR1 | |
| SCHEMBL22501665 | 0.78 | MAPK1 (0.52) | MAPK1HPGDSEDNRAEDNRBHCRTR1 | |
| SCHEMBL28164766 | 0.77 | HPGDS (0.46) | HPGDSLTA4HHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL9863754 | 0.77 | HPGDS (0.46) | MAPK1PRMT6HPGDSEDNRAEDNRB | |
| SCHEMBL1804513 | 0.77 | PRKCI (0.53) | MAPK1HPGDSATRLTA4HHCRTR1 | |
| SCHEMBL9454674 | 0.77 | HPGDS (0.46) | MAPK1PRMT6HPGDSEDNRAEDNRB | |
| SCHEMBL14983820 | 0.77 | HPGDS (0.43) | MAPK1PRMT6HPGDSEDNRAEDNRB | |
| SCHEMBL9507339 | 0.76 | HPGDS (0.53) | HPGDSLTA4HHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3964365 | 0.76 | HPGDS (0.58) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | MAPK1 3606/4885DHODH 135/4885PRMT6 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.